ASX:MSBBiotechs
Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week
Mesoblast (ASX:MSB) recently announced the availability of its groundbreaking therapy, Ryoncil, in the United States, yet its share price experienced a 15% decline over the past week. This downturn occurred despite the company's significant progress in healthcare innovation, following its inclusion in the S&P/ASX 200. External factors, like the volatile global market reacting to geopolitical concerns, also contributed to this decline, as broader market indices showed a mixed performance with...